Not all antibodies are equal

od Booth, Laurence
Izdano 2013

Repurposing Tecfidera for cancer

od Booth, Laurence, Malkin, Mark, Dent, Paul
Izdano u Aging (Albany NY) (2016)

Not the comfy chair! Cancer drugs that act against multiple active sites

od Booth, Laurence, Poklepovic, Andrew, Dent, Paul
Izdano u Expert Opin Ther Targets (2019)

Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies

od Dent, Paul, Booth, Laurence, Poklepovic, Andrew
Izdano u Immunometabolism (2019)

HSPA5/Dna K May Be a Useful Target for Human Disease Therapies

od Booth, Laurence, Roberts, Jane L., Dent, Paul
Izdano u DNA Cell Biol (2015)

Curcumin interacts with sildenafil to kill GI tumor cells via endoplasmic reticulum stress and reactive oxygen/ nitrogen species

od Roberts, Jane L., Poklepovic, Andrew, Booth, Laurence
Izdano u Oncotarget (2017)

The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells

od Booth, Laurence, Roberts, Jane, Poklepovic, Andrew, Dent, Paul
Izdano u Cancer Biol Ther (2018)

The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib

od Booth, Laurence A., Roberts, Jane L., Dent, Paul
Izdano u Semin Cancer Biol (2019)

PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Izdano u Oncotarget (2017)

[pemetrexed + sildenafil], via autophagy-dependent HDAC downregulation, enhances the immunotherapy response of NSCLC cells

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Izdano u Cancer Biol Ther (2017)

Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody

od Booth, Laurence, Roberts, Jane Lisa, Poklepovic, Andrew, Dent, Paul
Izdano u Cancer Biol Ther (2018)

NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Izdano u Oncol Signal (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Izdano u Front Oncol (2019)

GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

od Booth, Laurence, West, Cameron, Hoff, Daniel Von, Dent, Paul
Izdano u Front Oncol (2020)

Corrigendum: GZ17-6.02 and Doxorubicin Interact to Kill Sarcoma Cells via Autophagy and Death Receptor Signaling

od Booth, Laurence, West, Cameron, Von Hoff, Daniel, Dent, Paul
Izdano u Front Oncol (2021)

Rationally Repurposing Ruxolitinib (Jakafi(®)) as a Solid Tumor Therapeutic

od Tavallai, Mehrad, Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Dent, Paul
Izdano u Front Oncol (2016)

PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Gordon, Sarah, Dent, Paul
Izdano u Oncotarget (2016)

HDAC inhibitors enhance the immunotherapy response of melanoma cells

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Dent, Paul
Izdano u Oncotarget (2017)

Valproate augments Niraparib killing of tumor cells

od Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Poklepovic, Andrew, Dent, Paul
Izdano u Cancer Biol Ther (2018)

Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells

od Booth, Laurence, Roberts, Jane L., Kirkwood, John, Poklepovic, Andrew, Dent, Paul
Izdano u Adv Cancer Res (2018)